These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 9024711

  • 1. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
    Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A.
    Cancer; 1997 Feb 15; 79(4):730-9. PubMed ID: 9024711
    [Abstract] [Full Text] [Related]

  • 2. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
    Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D.
    Cancer; 1998 Sep 15; 83(6):1142-52. PubMed ID: 9740079
    [Abstract] [Full Text] [Related]

  • 3. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
    Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV.
    J Clin Oncol; 1996 Jul 15; 14(7):2000-11. PubMed ID: 8683230
    [Abstract] [Full Text] [Related]

  • 4. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
    Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M.
    Eur J Cancer; 1996 Mar 15; 32A(3):404-12. PubMed ID: 8814682
    [Abstract] [Full Text] [Related]

  • 5. ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer.
    Buzdar AU, Jonat W, Howell A, Plourde PV.
    J Steroid Biochem Mol Biol; 1997 Apr 15; 61(3-6):145-9. PubMed ID: 9365184
    [Abstract] [Full Text] [Related]

  • 6. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
    Milla-Santos A, Milla L, Portella J, Rallo L, Pons M, Rodes E, Casanovas J, Puig-Gali M.
    Am J Clin Oncol; 2003 Jun 15; 26(3):317-22. PubMed ID: 12796608
    [Abstract] [Full Text] [Related]

  • 7. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
    Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group.
    J Clin Oncol; 2005 Aug 01; 23(22):5108-16. PubMed ID: 15998903
    [Abstract] [Full Text] [Related]

  • 8. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P.
    J Clin Oncol; 2005 Aug 01; 23(22):5138-47. PubMed ID: 16009955
    [Abstract] [Full Text] [Related]

  • 9. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A.
    Breast Cancer Res Treat; 2004 Jun 01; 85(3):247-54. PubMed ID: 15111763
    [Abstract] [Full Text] [Related]

  • 10. Clinical overview of anastrozole--a new selective oral aromatase inhibitor.
    Jonat W.
    Oncology; 1997 Jun 01; 54 Suppl 2():15-8. PubMed ID: 9394855
    [Abstract] [Full Text] [Related]

  • 11. Focus on anastrozole and breast cancer.
    Mokbel K.
    Curr Med Res Opin; 2003 Jun 01; 19(8):683-8. PubMed ID: 14687437
    [Abstract] [Full Text] [Related]

  • 12. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.
    Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR.
    Clin Cancer Res; 2000 Jun 01; 6(6):2229-35. PubMed ID: 10873072
    [Abstract] [Full Text] [Related]

  • 13. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
    Cancer; 2003 Nov 01; 98(9):1802-10. PubMed ID: 14584060
    [Abstract] [Full Text] [Related]

  • 14. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
    Miller WR, Stuart M, Sahmoud T, Dixon JM.
    Br J Cancer; 2002 Oct 21; 87(9):950-5. PubMed ID: 12434282
    [Abstract] [Full Text] [Related]

  • 15. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C.
    Cancer; 2003 Jul 15; 98(2):229-38. PubMed ID: 12872340
    [Abstract] [Full Text] [Related]

  • 16. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
    Buzdar AU.
    Expert Rev Anticancer Ther; 2002 Dec 15; 2(6):623-9. PubMed ID: 12503208
    [Abstract] [Full Text] [Related]

  • 17. Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
    Lavrenkov K, Man S, Geffen DB, Cohen Y.
    Isr Med Assoc J; 2002 Mar 15; 4(3):176-7. PubMed ID: 11908256
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
    Mouridsen H, Chaudri-Ross HA.
    Oncologist; 2004 Mar 15; 9(5):497-506. PubMed ID: 15477634
    [Abstract] [Full Text] [Related]

  • 19. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH, Johnson JR, Li N, Chen G, Pazdur R.
    Clin Cancer Res; 2002 Mar 15; 8(3):665-9. PubMed ID: 11895893
    [Abstract] [Full Text] [Related]

  • 20. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
    Wiseman LR, Adkins JC.
    Drugs Aging; 1998 Oct 15; 13(4):321-32. PubMed ID: 9805213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.